159 related articles for article (PubMed ID: 37404092)
21. An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy.
Li W; Zhu X; Zhou X; Wang X; Zhai W; Li B; Du J; Li G; Sui X; Wu Y; Zhai M; Qi Y; Chen G; Gao Y
J Control Release; 2021 Jun; 334():376-388. PubMed ID: 33940058
[TBL] [Abstract][Full Text] [Related]
22. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.
Lucas ML; Heller L; Coppola D; Heller R
Mol Ther; 2002 Jun; 5(6):668-75. PubMed ID: 12027550
[TBL] [Abstract][Full Text] [Related]
23. An injectable thermosensitive photothermal-network hydrogel for near-infrared-triggered drug delivery and synergistic photothermal-chemotherapy.
Liu C; Guo X; Ruan C; Hu H; Jiang BP; Liang H; Shen XC
Acta Biomater; 2019 Sep; 96():281-294. PubMed ID: 31319202
[TBL] [Abstract][Full Text] [Related]
24. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
25. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
[TBL] [Abstract][Full Text] [Related]
26. Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy.
Jiang J; Zhang Y; Peng K; Wang Q; Hong X; Li H; Fan G; Zhang Z; Gong T; Sun X
Acta Biomater; 2017 Oct; 61():114-123. PubMed ID: 28483693
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy with injectable hydrogels to treat obstructive nephropathy.
Soranno DE; Lu HD; Weber HM; Rai R; Burdick JA
J Biomed Mater Res A; 2014 Jul; 102(7):2173-80. PubMed ID: 23913854
[TBL] [Abstract][Full Text] [Related]
28. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
29. Dual delivery of an NF-κB inhibitor and IL-10 through supramolecular hydrogels polarizes macrophages and promotes cardiac repair after myocardial infarction.
Wang D; Hu Y; Zhang L; Cai H; Wang Y; Zhang Y
Acta Biomater; 2023 Jul; 164():111-123. PubMed ID: 37001840
[TBL] [Abstract][Full Text] [Related]
30. DOX/IL-2/IFN-γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment.
Lv Q; He C; Quan F; Yu S; Chen X
Bioact Mater; 2018 Mar; 3(1):118-128. PubMed ID: 29744449
[TBL] [Abstract][Full Text] [Related]
31. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
33. Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.
Saeed M; Zalba S; Seynhaeve ALB; Debets R; Ten Hagen TLM
Int J Nanomedicine; 2019; 14():2069-2089. PubMed ID: 30988609
[TBL] [Abstract][Full Text] [Related]
34. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.
Werthmöller N; Frey B; Wunderlich R; Fietkau R; Gaipl US
Cell Death Dis; 2015 May; 6(5):e1761. PubMed ID: 25973681
[TBL] [Abstract][Full Text] [Related]
35. Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence.
Wanjale MV; Sunil Jaikumar V; Sivakumar KC; Ann Paul R; James J; Kumar GSV
Int J Nanomedicine; 2022; 17():2203-2224. PubMed ID: 35599751
[TBL] [Abstract][Full Text] [Related]
36. Trp2 Peptide-Assembled Nanoparticles with Intrinsically Self-Chelating
He Z; Jia H; Zheng M; Wang H; Yang W; Gao L; Zhang Z; Xue J; Xu B; Yang W; Xing G; Gao X; Gao F
ACS Appl Bio Mater; 2021 Jul; 4(7):5707-5716. PubMed ID: 35006752
[TBL] [Abstract][Full Text] [Related]
37. Gene electrotransfer of IL-2 and IL-12 plasmids effectively eradicated murine B16.F10 melanoma.
Komel T; Bosnjak M; Kranjc Brezar S; De Robertis M; Mastrodonato M; Scillitani G; Pesole G; Signori E; Sersa G; Cemazar M
Bioelectrochemistry; 2021 Oct; 141():107843. PubMed ID: 34139572
[TBL] [Abstract][Full Text] [Related]
38. Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy.
Gong Y; Chen M; Tan Y; Shen J; Jin Q; Deng W; Sun J; Wang C; Liu Z; Chen Q
ACS Appl Mater Interfaces; 2020 Nov; 12(45):50248-50259. PubMed ID: 33135879
[TBL] [Abstract][Full Text] [Related]
39. Dendritic Cell-Derived Exosomes Driven Drug Co-Delivery Biomimetic Nanosystem for Effective Combination of Malignant Melanoma Immunotherapy and Gene Therapy.
Lin J; Huang N; Li M; Zheng M; Wang Z; Zhang X; Gao H; Lao Y; Zhang J; Ding B
Drug Des Devel Ther; 2023; 17():2087-2106. PubMed ID: 37489176
[TBL] [Abstract][Full Text] [Related]
40. Injectable supramolecular hydrogel formed from α-cyclodextrin and PEGylated arginine-functionalized poly(l-lysine) dendron for sustained MMP-9 shRNA plasmid delivery.
Lin Q; Yang Y; Hu Q; Guo Z; Liu T; Xu J; Wu J; Kirk TB; Ma D; Xue W
Acta Biomater; 2017 Feb; 49():456-471. PubMed ID: 27915016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
